SLC5A2 and kidney failure: Taken together, the data from the DECLARE-TIMI 58 and DAPA-CKD trials provide compelling evidence to initiate treatment with SGLT2 inhibitors to prevent kidney failure, heart failure hospitalisations or cardiovascular death in patients with type 2 diabetes regardless of kidney function or albuminuria status.